The abstract for the oral presentation that will be given on the 24th will be released from embargo on the 11th. That abstract will provide an overview of early ReACT results and indicate both why management decided to expand ReACT into a "confirmatory" arm with FDA registrational implications and also why the scientific conference board decided to grant CLDX an oral presentation on the trial. So, yes: more information will be released via conference abstract on the 11th.
On the 24th, management will release updated ReACT data (that goes beyond what was known at the time that the abstract was submitted during the summer) concurrent with the oral presentation at the conference. On the 25th, management will host a conference call to discuss the updated data.